PreHospital Air Medical Plasma Trial (PAMPer)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01818427 |
|
Recruitment Status :
Completed
First Posted : March 26, 2013
Results First Posted : October 9, 2018
Last Update Posted : April 8, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hemmorhagic Shock During Air Medical Transport | Biological: infusion of 2 units of plasma | Phase 3 |
Background: Although advances in the care of the severely injured patient have occurred over the last decade, patients continue to be plagued with uncontrolled hemorrhage resulting in significant early mortality and the development of multiple organ failure and associated complications. A primary driving force for this unbridled hemorrhage has been shown to be the early coagulopathy which complicates severe injury. Increasing evidence suggests that blood component transfusion protocols that address this early coagulopathy, once a patient arrives at a trauma center, are associated with lower mortality and a reduction in blood component transfusion requirements. Prehospital interventions which quell this early coagulopathy in an earlier setting have the potential to minimize or even prevent this vicious hemorrhagic cascade, further lowering blood component transfusion requirements and reducing the resultant morbid sequelae which complicates severe injury.
Objective/Hypothesis: The primary hypothesis will be that prehospital infusion of plasma during air medical transport in patients with hemorrhagic shock will lower 30 day mortality. The secondary hypotheses include that prehospital infusion of plasma will reduce 24 hour blood transfusion, multiple organ failure, nosocomial infection, and acute lung injury, reduce or prevent the early coagulopathy as demonstrated by improving presenting coagulation and thromboelastography parameters, and reduce the early inflammatory cytokine response, thrombomodulin and increase protein C levels.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 523 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Health Services Research |
| Official Title: | Prehospital Air Medical Plasma (PAMPer) Phase III Multicenter, Prospective, Randomized, Open-label, Interventional Trial A Four Year Multicenter Open Label Randomized Trial |
| Study Start Date : | May 2014 |
| Actual Primary Completion Date : | September 2017 |
| Actual Study Completion Date : | September 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: plasma
infusion of 2 units of plasma
|
Biological: infusion of 2 units of plasma
infusion of 2 units of plasma |
|
No Intervention: standard air medical care
control group
|
- Our Primary Outcome for the Proposal Will be 30 Day Mortality [ Time Frame: 30 days ]All cause 30 day mortality using imputation for those with missing 30 day mortality.
- Twenty Four-Hour Blood Transfusion Requirements [ Time Frame: at twenty four hours ]24-hour blood transfusion requirements will be determined by recording blood volume (mls) and number of Units transfused from the time of trauma bay arrival or upon completion of pre-hospital initiated plasma infusion. For survival bias analysis, volumes and number of blood transfusion Units received at 3, 6, 12, and 18 hours will also be recorded.
- In-hospital Mortality [ Time Frame: during hospitalization ]In hospital mortality will be prospectively recorded from the time of trauma bay arrival. Over the first 24 hours we will document and record the time of death in hours, while after the 24 hour time point, we will document and record the time of death in days from arrival. We suspect that patients in hemorrhagic shock will have a significant percentage of mortality occurring in the first 24 hour period.
- Multiple Organ Failure [ Time Frame: during hospitalization ]Organ dysfunction will be evaluated via a well-validated scoring system referred to as the Multiple Organ Dysfunction Score (MODScore). Patients who are never admitted to the ICU or those with a length of ICU stay of less than 48 hours will be considered to have a MODScore of 0. A summary of the MODScore may be calculated by summing the worst scores of each of the individual systems over the course of the ICU stay (Table 1). A summary MODScore > 5 will be classified as multiple organ failure (MOF). Scores will be determined daily up until post injury day 28 or ICU discharge.
- Acute Lung Injury (ALI) and Transfusion Related Acute Lung Injury (TRALI) [ Time Frame: hospitalization ]Development of ALI will be assessed which includes: 1) bilateral infiltrates on chest x-ray, 2) a capillary wedge pressure < 18mmHg, and 3) Pao2/Fio2 ratio < 300 via blood gas analysis. In those patients without a Swan-Ganz catheter to determine capillary wedge pressure, the absence of signs of, or clinical concern, for elevated left sided atrial pressures will be used for the diagnosis. All patients who remain intubated beyond the first 24 hours post-injury will be evaluated using blood gas analysis and chest x-ray evaluation. Those patients who remain intubated at 48 hours through 7 days will be reevaluated for this outcome at these time points. The diagnosis of TRALI will be defined as when ALI occurs within the first 6 hours from arrival at the trauma center as it is clinically defined.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: Hemorrhagic shock not responsive to crystalloid infusion -
Exclusion Criteria: Isolated Fall, Cervical cord injury, prisoner, pregnant patient, traumatic arrest
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01818427
| United States, Pennsylvania | |
| University of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Principal Investigator: | Jason L Sperry, MD,MPH | University of Pittsburgh |
Documents provided by Jason Sperry, University of Pittsburgh:
| Responsible Party: | Jason Sperry, MD, MPH, University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT01818427 |
| Other Study ID Numbers: |
11152002 IND 15117 |
| First Posted: | March 26, 2013 Key Record Dates |
| Results First Posted: | October 9, 2018 |
| Last Update Posted: | April 8, 2021 |
| Last Verified: | April 2021 |
|
hemmorhagic shock, plasma, air medical transport, randomized, multicenter |
|
Shock Pathologic Processes |